GBGianni Bonadonna

Gianni Bonadonna

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gianni Bonadonna has a total of 96 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Management of breast cancer after childhood cancer and Hodgkin’s lymphoma.

    by M. Terenziani, S. Viviani, M. Massimino, A. Moliterni, M. Gennaro, L. Gandola, L. Boschetti, S. Catania, G. Cefalo, A. Di Russo, et al.

    1566 Background: The risk of developing a secondary breast cancer (SBC) among women receiving chest radiotherapy (RT) for pediatric cancer and Hodgkin lymphomas (HL) is well established. The present study analyzes the clinical characteristics, pathology, management and prognosis of BC occurring after RT. Methods: From 1980 to 2010, 80 cases of SBC in a series of 76 survivors were diagnosed. These patients were treated from 1965 to 1992 with RT +/- chemotherapy for pediatric cancer or HL at Milan Cancer Institute. The histology, grading, nodal status, hormone receptor status, stage of the SBC, type of chemotherapy and surgery, disease free and overall survival were analyzed. Results: The median age at diagnosis of first neoplasms and of SBC was 18 and 38 years, respectively. The main histological features and the hormone receptor status paralleled the frequency observed in the case series of primary BC treated in the same Institution in the similar period of time. 67% of the tumors had ductal histology, 62% had positive estrogen receptor, 50% presented with pN0 and 68% with pT1 tumors. The incidence of bilateral synchronous SBC was 5%. In 59% of patients (41) adjuvant chemotherapy was administered, including antracyclines in 43% of this subgroup, followed by endocrine therapy in hormone positive receptor tumors only. Conservative surgery was feasible in 43 women (56%) and despite prior chest irradiation, subsequent breast RT was delivered in 33 of them. The five year disease free survival, overall and specific BC survival were 47%, 78% and 79%, respectively. Conclusions: Clinical characteristics, pathology and outcomes of SBC among this series of young women are similar to those observed in primary BC. Conservative surgery and repeat irradiation is also possible, without tissue necrosis. Despite previous therapies for their first malignancy, in a specialized institution patients with SBC can be managed in the same way as primary BC and carries similar chances of cure.

  • Fertility in young patients treated with chemotherapy for Hodgkin’s disease (HD): Long-term results

    by S. Viviani, V. Bonfante, G. Ragni, G. Bonadonna, P. Valagussa, A. M. Gianni

    6578 Background: Due to improved lymphoma cure rates, long-term toxicity, including iathrogenic sterility, is of great concern. We thus evaluated the fertility of patients (pts) treated for HD at the Istituto Nazionale Tumori of Milan from 1990 to 2001 with three different chemotherapy (CT) regimens +/- radiotherapy excluding pelvic nodes. Material and Methods: The case series included 191 pts (73 males,118 females), median age 27 years (range 18–45), in long-lasting complete remission after three different CT regimens: 119 pts received 4–6 cycles of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine); 48 pts were given 6–8 cycles of VEBEP (VP16, epirubicin, bleomycin, cyclophosphamide, prednisone) and 25 pts were treated with sequential CT including intermediate-high doses of epirubicin, vincristine, prednisone, cyclophosphamide and etoposide for a 3 months period. Fertility was evaluated by semen analysis and conceptions in males and by history of menstrual cycles and pregnancies in females. WHO criteria were used to classify normospermia, azoospermia, abnormal semen (all sperm abnormalities but azoospermia), amenorrhea and normorrhea. Results: Males: after ABVD we observed permanent azoospermia in 6%, abnormal semen in 70% and normal semen in 24%; 30% of pts fathered. After VEBEP we documented permanent azoospermia in 35%, abnormal semen in 46% and normal semen in 19%; 27% of pts fathered. After sequential CT permanent azoospermia occurred in 33% and abnormal semen in 67%; 11% of pts fathered. Females: definitive amenorrhea was documented in 2% after ABVD, 17% after VEBEP and 6% after sequential CT; all pts who became amenorrheic were aged > 30 years at treatment. Pregnancies occurred in 38%, 21% and 25% in each treatment group respectively. Conclusions: Long-term results confirm that ABVD spares fertility in the majority of cases. Regimens containing alkylating agents, like VEBEP or sequential CT, induce sterility in less than 20% of women, but in a large fraction of male pts. Therefore pretreatment cryopreservation of semen should be offered to all males. No significant financial relationships to disclose.


  • Open Access

    Menopausal status dependence of the timing of breast cancer recurrence after surgical removal of the primary tumour

    by Romano Demicheli, Gianni Bonadonna, William Jm Hrushesky, Michael W Retsky, Pinuccia Valagussa

    Introduction: Information on the metastasis process in breast cancer patients undergoing primary tumour removal may be extracted from an analysis of the timing of clinical recurrence. Methods: The hazard rate for local-regional and/or distant recurrence as the first event during the first 4 years after surgery was studied in 1173 patients undergoing mastectomy alone as primary treatment for operable breast cancer. Subset analyses were performed according to tumour size, axillary nodal status and menopausal status. Results: A sharp two-peaked hazard function was observed for node-positive pre-menopausal patients, whereas results from node-positive post-menopausal women always displayed a single broad peak. The first narrow peak among pre-menopausal women showed a very steep rise to a maximum about 8–10 months after mastectomy. The second peak was considerably broader, reaching its maximum at 28–30 months. Post-menopausal patients displayed a wide, nearly symmetrical peak with maximum risk at about 18–20 months. Peaks displayed increasing height with increasing axillary lymph node involvement. No multi-peaked pattern was evident for either pre-menopausal or post-menopausal node-negative patients; however, this finding should be considered cautiously because of the limited number of events. Tumour size influenced recurrence risk but not its timing. Findings resulting from the different subsets of patients were remarkably coherent and each observed peak maintained the same position on the time axis in all analysed subsets. Conclusions: The risk of early recurrence for node positive patients is dependent on menopausal status. The amount of axillary nodal involvement and the tumour size modulate the risk value at any given time. For pre-menopausal node-positive patients, the abrupt increase of the first narrow peak of the recurrence risk suggests a triggering event that synchronises early risk. We suggest that this event is the surgical removal of the primary tumour. The later, broader, more symmetrical risk peaks indicate that some features of the corresponding metastatic development may present stochastic traits. A metastasis development model incorporating tumour dormancy in specific micro-metastatic phases, stochastic transitions between them and sudden acceleration of the metastatic process by surgery can explain these risk dynamics.


  • The timing of breast cancer recurrence after mastectomy and adjuvant CMF chemotherapy supports a dormancy-based model for metastatic development

    by R. Demicheli, G. Bonadonna, W. J. M. Hrushesky, A. Moliterni, M. W. Retsky, P. Valagussa, M. Zambetti

    9573 Background: Adjuvant chemotherapy may be regarded as a probe revealing features of the metastasis development, by changes induced in the recurrence timing. Methods: Two randomized clinical trials and a historical group of axillary node positive patients undergoing mastectomy, all treated at the Ist. Naz. Tumori of Milan, were analyzed. Study 1 involved 386 women (no further treatment vs. 12 cycles of CMF), Study 2 involved 459 women (6 vs. 12 cycles of CMF) and the historical group involved 575 patients (mastectomy alone). Discrete hazards of early recurrence (over 4 years), and recurrence risk reductions for treated patients relative to controls were estimated. Results: 1) recurrence rate reduction by CMF is mainly restricted to specific, temporally separate recurrence clusters at the first and third year, while the second-year recurrences are weakly affected; 2) prolonging adjuvant treatment from 6 to 12 months partially changes the recurrence timing, without affecting the overall treatment effectiveness; 3) findings are menopausal status independent. Conclusions: At least two different proliferative events, resulting in clinical appearance of the two metastasis clusters, should be assumed as occurring during treatment administration, when some other metastases are in a rather refractory status. The time distributions of both post treatment recurrence risk and CMF effectiveness are similar for both menopausal statuses, suggesting that the metastatic mechanisms may be substantially the same, although differently modulated. Cytotoxic chemotherapy changes differing recurrence dynamics of pre and post menopausal women to a common later recurrence pattern. These findings give further support to a metastasis development model based on tumour dormancy in specific micro-metastatic phases (single cells and avascular foci) and on acceleration of the metastatic process due to surgery. No significant financial relationships to disclose.

  • Open Access

    Multimodal treatment with primary single-agent epirubicin in operable breast cancer: 5-year experience of the Michelangelo Cooperative Group

    by G. Bonadonna, M. Zambetti, C. Bumma, M. Donadio, A. Bolognesi, G. Robustelli della Cuna, G. Ambrosini, G. Lelli, M. Mansutti, P. Verderio, et al.

    Background: To assess the efficacy of primary single-agent epirubicin (120 mg/m2 every 3 weeks for three cycles) in reducing tumor burden in operable breast cancer ≥2.5 cm in largest diameter at diagnosis and its effect on the rate of conservative surgery. Patients and methods: A total of 319 eligible patients, who were all candidates for mastectomy, were enrolled on to a multicenter prospective non-randomized study. Tumor response was assessed clinically and pathologically. Relapse-free and overall survival were assessed on major prognostic variables. Results: After primary epirubicin, complete disappearance of invasive neoplastic cells accounted for only 2.6% of patients, but 40% of patients had their primary tumor downstaged to ≤2 cm in diameter. Conservative surgery was performed in 67% of patients. At a median follow-up of 5 years, both primary tumor size at diagnosis (P P Conclusions: This multicenter study confirms that three cycles of full-dose epirubicin can avoid mutilating surgery in a high proportion of patients with tumors not amenable to primary conservative surgery. This multimodal treatment can be safely administered outside of clinical trials in patients presenting with large tumors and with a desire to preserve their body integrity.


    • 1 July 2001
      • Vol. 64, 51-5

    High-dose ifosfamide and vinorelbine as salvage therapy for relapsed or refractory Hodgkin's disease.

    by V Bonfante, S Viviani, L Devizzi, A Di Russo, M Di Nicola, M Magni, P Matteucci, S Grisanti, P Valagussa, G Bonadonna, et al.

    In an effort to improve results in patients with relapsed or refractory Hodgkin's disease (HD), an intensive regimen combining vinorelbine (25 mg/m2 i.v. days 1 and 5) and high-doses of ifosfamide (3000 mg/m2/d, days 1-4 by continuous infusion) with mesna uroprotection and G-CSF support was designed. Forty-seven patients were treated; 14 had failure to initial induction therapy and 33 had disease relapsed from an initial response. The response rate was 83%, with 21 complete (45%, CR) and 18 partial remissions (38%, PR). Partial response was achieved after a median of two cycles (range 1-3) and CR after a median of six cycles (range 2-10). At the end of ifosfamide and vinorelbine, 10 patients in CR, one in PR, and one with stable disease also received radiotherapy to nodal sites of relapse. Eleven patients who had undergone peripheral blood stem cell (PBSC) harvesting following ifosfamide-vinorelbine proceeded to receive high-dose chemotherapy (HDCT) and PBSC transplantation. The main toxic effect was grade III-IV neutropenia, documented in 65% of cycles with a median duration of 4 days, and non-haematological toxicity was mild. The combination of high-doses of ifosfamide and vinorelbine was well tolerated and an active regimen in treatment of patients with relapsed and refractory HD. It was not only useful as salvage therapy with or without consolidative radiotherapy but it also was a valuable induction regimen before high-dose intensification therapy followed by PBSC reinfusion in patients eligible for this approach.


    • 28 February 2001
      • Vol. 86, S9-10

    [Adjuvant chemotherapy in breast cancer. New strategies].

    by P Valagussa, G Bonadonna, L Gianni

  • Open Access

    Historical Review of Hodgkin's Disease

    by Gianni Bonadonna


    • 20 October 1999
      • Vol. 5  (5) , 275-82

    Long-term results of an intensive regimen: VEBEP plus involved-field radiotherapy in advanced Hodgkin's disease.

    by S Viviani, V Bonfante, A Santoro, M Zanini, L Devizzi, A D Di Russo, F Soncini, F Villani, G Ragni, P Valagussa, et al.

    This pilot study was conducted to evaluate the efficacy and toxicity of a new intensive drug regimen, combined with involved-nodal-field radiotherapy, in advanced Hodgkin's disease not treated by chemotherapy. From September 1990 to March 1993, 73 evaluable patients with newly diagnosed stage IIB, III (A and B), and IV (A and B) Hodgkin's disease or who were relapsing after primary subtotal or total nodal irradiation were treated with eight cycles of etoposide, epirubicin, bleomycin, cyclophosphamide, and prednisolone (VEBEP) followed by radiotherapy (30-36 Gy) to the nodal site or sites of pretreatment disease. The median duration of follow-up was 68 months. The complete remission rate was 94% (95% CI: 86-98). At 6 years, freedom from progression and overall survival rates were 78% (95% CI: 68-88) and 82% (95% CI: 73-91), respectively. There was one episode of fatal sepsis after bone marrow aplasia that occurred after VEBEP and extended-field irradiation. Hematologic toxicity during chemotherapy was acceptable; without the support of growth factors, grade IV leukopenia and grade IV neutropenia, as determined within cycles, occurred in 38% and 85% of patients, respectively, but was reversible in the vast majority of patients by the day of treatment recycle. No episodes of epidoxorubicin-related cardiomyopathy or symptomatic pulmonary toxicity were documented. Overt and/or subclinical hypothyroidism occurred in 38% of cases. Gonadal damage was evident in the large majority of male patients but reversible in half of them, whereas permanent sterility was observed in females at least 35 years of age. No secondary leukemia has been so far detected. VEBEP followed by involved-nodal-field radiotherapy is an effective treatment for chemotherapy-naive Hodgkin's disease and is associated to acceptable rates of acute and intermediate-term toxicity. This intensive regimen, which does not routinely require the support of hematopoietic growth factors and can be delivered in an outpatient setting, warrants a prospective comparison in a randomized trial versus one of the more effective standard-combination regimens.


    • 31 August 1999
      • Vol. 70  (3) , 359-69

    [Primary chemotherapy in operable breast carcinoma].

    by G Bonadonna, P Valagussa

    We have reviewed the current status of primary chemotherapy for resectable breast cancer. Available findings indicate that the most immediate benefit of this treatment approach consists in an important tumor shrinkage, enabling to significantly increase the rates of breast conserving approaches. In spite of the logical and scientific rationale, available data from prospective randomized studies do not provide evidence of a clear superiority of primary chemotherapy over adjuvant chemotherapy. Nevertheless, the observed kinetic acceleration of micrometastases following noncurative surgical excision in animal studies represents a strong biologic evidence supporting primary chemotherapy. From a clinical perspective, primary chemotherapy with conventional regimens can induce a low to moderate rate of pathological complete remissions that appear to be an important marker of favorable treatment outcome. For this reason, well designed, prospectively randomized, large trials with drug regimens more effective than those used so far are mandatory to demonstrate the real worthiness of this newer treatment approach and to define the optimal timing of surgery and other locoregional modalities in respect to the long-term treatment outcome. Should there be no benefit to the use of primary drug treatment, then the biologic consequences of primary tumor removal, as observed in experimental models, are not likely to be of clinical significance. Nonetheless, since primary chemotherapy can achieve long-term results similar to those obtained with postoperative drug treatment while increasing the frequency of breast-sparing approaches, women can be offered a choice to maintain their body integrity. Should improved pathological complete remission rates from more effective regimens of primary chemotherapy translate into improved survival compared with the classical postoperative modality, then, regardless of the tumor diameter at diagnosis, our overall strategy for the management of operable breast cancer will require a radical departure from the traditional dogma.